Vol 12, Supp. B (2021)
Case report
Published online: 2021-06-11

open access

Page views 312
Article views/downloads 372
Get Citation

Connect on Social Media

Connect on Social Media

Eltrombopag in the treatment of patient with immune thrombocytopenia and atrial fibrillation

Michał Witkowski1, Magdalena Witkowska2, Tadeusz Robak13

Abstract

Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease that is diagnosed when the platelet count is below 100 G/L and there are no other causes of thrombocytopenia. The incidence of ITP is 9.5/100,000. Atrial fibrillation (AF) is the most common sustained arrhythmia, and its incidence increases with age. The incidence of AF is 2%, and increases to ~4% in the 60–70 age group. Based on previous publications, it has been proven that ITP does not reduce the incidence of thromboembolic complications, and even increases their risk. Anticoagulation in ITP. patients is particularly difficult as we balance between thromboembolic and hemorrhagic complications. The above study presents a patient with paroxysmal AF, additionally diagnosed with ITP. resistant to many lines of treatment. Thanks to the use of eltrombopag, it was possible to increase the value of platelets and safely administer anticoagulant therapy.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Provan D, Arnold D, Bussel J, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019; 3(22): 3780–3817.
  2. Michel M. Immune thrombocytopenic purpura: epidemiology and implications for patients. Eur J HaematolSuppl. 2009; 71: 3–7.
  3. Charakterystyka Produktu Leczniczego. Eltrombopag. https://ec.europa.eu/health/documents/community-register/2017/20170216137166/anx_137166_pl.pdf (November 16, 2020).
  4. Zoni-Berisso M, Lercari F, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014; 6: 213–220.
  5. Witkowski M, Bissinger A, Grycewicz T, et al. Asymptomatic atrial fibrillation in patients with atrial fibrillation and implanted pacemaker. Int J Cardiol. 2017; 227: 583–588.
  6. Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020.
  7. Nørgaard M, Severinsen M, Maegbaek ML, et al. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2012; 159(1): 109–111.
  8. Balitsky AK, Kelton J, Arnold D. Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score. Blood. 2018; 132(25): 2684–2686.
  9. Rand ML, Dean JA. Platelet function in autoimmune (idiopathic) thrombocytopenic purpura. Acta Paediatrica. 2007; 424: 57–60.
  10. Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010; 95(7): 1167–1175.
  11. Friberg L, Rosenqvist M, Lip G. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012; 33(12): 1500–1510.
  12. Brotman DJ, Girod J, Posch A, et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res. 2006; 118(2): 247–252.
  13. van der Hooft CS, Heeringa J, Brusselle G, et al. Corticosteroids and the risk of atrial fbrillation. Arch Intern Med. 2006; 166(9): 1016.
  14. Paran D, Herishanu Y, Elkayam O, et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis Int J Haemost Thromb. 2005; 16(5): 313–318.
  15. Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase® — Abstract — Europe PMC. https://europepmc.org/article/med/26338346 (November 16, 2020).
  16. Ahn YS, Horstman L, Jy W, et al. Vascular dementia in patients with immune thrombocytopenic purpura. Thromb Res. 2002; 107(6): 337–344.
  17. Grygier M, Wojakowski W, Smolka G, et al. Left atrial appendage occlusion: consensus document of Association of Cardiovascular Interventions and Heart Rhythm Section of Polish Cardiac Society. Kardiol Pol. 2018: 677–697.
  18. Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation. JAMA. 2014; 312(19): 1988–1998.
  19. Page LK, Psaila B, Provan D, et al. The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol. 2007; 138(2): 245–248.
  20. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113(11): 2386–2393.



Hematology in Clinical Practice